One commonly used long-acting treatment combines cabotegravir and rilpivirine. These medicines work through different mechanisms to prevent HIV from multiplying. Cabotegravir belongs to the integrase strand transfer inhibitor group, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they help suppress viral replication.
Injectable treatment is not suitable for everyone. Healthcare professionals evaluate an individual's treatment history, viral suppression status, medical history, and potential drug interactions before recommending this approach.
Important aspects of injectable HIV therapy include:
Treatment eligibility: Patients generally need to have an undetectable or suppressed viral load before switching to the approved long-acting treatment.
Administration schedule: Injections are usually administered every one or two months, depending on the prescribed regimen.
Medical supervision: Healthcare professionals administer the injections and monitor possible side effects.
Treatment adherence: Attending scheduled appointments is essential to maintaining appropriate medication levels.
Oral medication considerations: Some treatment plans involve oral medication before injections or temporary oral medication when an injection appointment is delayed.
Possible side effects include injection-site pain, swelling, headache, fever, fatigue, and nausea. Patients should discuss persistent or severe symptoms with their healthcare professionals.
Viral load monitoring measures the amount of HIV RNA present in a blood sample. It is one of the most important laboratory methods used to understand how well HIV treatment is controlling the virus.
When antiretroviral treatment works effectively, viral load generally decreases to very low levels. Many people receiving successful treatment achieve an undetectable viral load. This means the amount of HIV in the blood is below the detection limit of the laboratory test. It does not mean HIV has been completely eliminated from the body.
Regular viral load testing helps healthcare professionals assess whether injectable treatment continues to provide adequate viral suppression. Monitoring is particularly important when beginning a new treatment, changing medication schedules, or investigating possible treatment failure.
Key considerations in viral load monitoring include:
Baseline testing: Viral load measurements help establish the patient's HIV status before treatment changes.
Follow-up testing: Healthcare professionals schedule laboratory tests to evaluate treatment response.
Detecting viral rebound: An increase in viral load may indicate missed injections, medication resistance, or other treatment-related problems.
Resistance assessment: Additional testing may be recommended when viral suppression is not maintained.
Treatment evaluation: Results help clinicians determine whether the existing treatment approach remains appropriate.
Viral load results are generally reported as copies of HIV RNA per millilitre of blood. Interpretation depends on the laboratory method, previous results, and individual clinical circumstances.
People receiving injectable HIV therapy should maintain regular appointments and follow their prescribed testing schedule. If viral load increases, healthcare professionals may repeat testing and investigate possible reasons before making treatment decisions. Consistent monitoring, timely injections, and communication with the treating team remain important parts of long-term HIV management.